Clinical Trials Logo

Clinical Trial Summary

Wegener's granulomatosis (WG) is a rare disease that causes inflammation of blood vessels, or vasculitis. It may involve many different parts of the body, but typically affects the upper and lower respiratory tract and kidneys. The purpose of this study is to determine the safety and effectiveness of the medication abatacept in treating adults with mild relapsing WG.


Clinical Trial Description

Current standard treatment for WG involves various medications and is based on disease severity. Unfortunately, more than 50% of people experience a relapse after remission, placing them at risk for additional organ damage and medication toxicity. To prevent this, safer and more effective treatments for mild relapses are needed. Several studies have shown that activated T cells, a type of white blood cell important in regulating immune responses, play a role in WG. Abatacept, an immunoglobulin-based medication approved by the FDA to treat rheumatoid arthritis, acts by preventing T-cell activation and may be useful in treating mild relapses of WG. The purpose of this study is to determine the safety and effectiveness of abatacept in treating adults with mild relapsing WG.

Participants will receive abatacept intravenously at study visits on Days 1, 15, and 29, and then once a month thereafter. A participant's abatacept dose is based on body weight and will remain the same throughout the study. Participants who are receiving maintenance immunosuppressive medications consisting of methotrexate, azathioprine, or mycophenolate mofetil at the time of enrollment will remain on these medications without dosage increase or reduction. Eligible participants may be on up to prednisone 15mg daily at the time of relapse. Following the development of relapse, participants may be treated with up to prednisone 30mg daily if necessary, but must to be back to the same dose that they had been on prior to relapse by Month 2. All study visits include medication review, physical exam, blood and urine collection, and questionnaires. A chest x-ray, computed tomography (CT) scan of the chest and sinuses, and lung function testing will occur at some study visits. Participants whose symptoms did not improved by Month 2 will be taken off abatacept. Any participants undergoing early termination or, after common closing, will undergo three follow-up study visits at 1, 3, and 6 months after the end of treatment. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00468208
Study type Interventional
Source University of Pennsylvania
Contact
Status Completed
Phase Phase 1/Phase 2
Start date February 2008
Completion date August 2011

See also
  Status Clinical Trial Phase
Terminated NCT00747461 - Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Phase 4
Completed NCT00072592 - An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Phase 1
Recruiting NCT02593565 - Vasculitis Pregnancy Registry
Completed NCT01167491 - Study of One Protein Implicated in Wegener Disease N/A
Completed NCT00307593 - RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides N/A
Active, not recruiting NCT00006055 - Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases N/A
Terminated NCT01408836 - Plasma Exchange for Renal Vasculitis Phase 2/Phase 3
Completed NCT00001473 - Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides N/A
Completed NCT00001256 - Steroids and Methotrexate to Treat Systemic Vasculitis Phase 2
Completed NCT00040248 - Daclizumab to Treat Wegener's Granulomatosis Phase 2
Completed NCT00005007 - Etanercept for Wegener's Granulomatosis Phase 2/Phase 3
Completed NCT00307671 - Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Phase 4
Completed NCT01988506 - Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Phase 2
Recruiting NCT01066208 - American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis N/A
Completed NCT00104299 - Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Phase 2/Phase 3
Completed NCT00753103 - Anti-Cytokine Therapy for Vasculitis Phase 2
Completed NCT02176070 - Reproductive Health in Men and Women With Vasculitis N/A
Completed NCT00004567 - Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes Phase 2
Completed NCT00001901 - Etanercept to Treat Wegener's Granulomatosis Phase 2
Completed NCT00430105 - Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Phase 2/Phase 3